At a glance
ClinicalIndex Comparison RecordPhase 2Active· 80 enrolled
Drug / intervention
Cisplatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Every 3 Week Versus Weekly Cisplatin Concurrent With Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Correlation With Oxidative Stress Markers
In Brief
A Phase 2 clinical trial evaluating Cisplatin and XRT for Carcinoma, Squamous Cell and Head and Neck Cancer. Active but no longer recruiting, targeting 80 participants across 1 site.
Detailed Summary
Patients will receive standard of care radiation therapy to the primary tumor of the head and neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or every 3-week cisplatin in locally advanced SCCHN. The relationship between cisplatin toxicity and the level of reactive oxygen species generated by the drug in subjects with squamous cell carcinoma of the head and neck treated on this trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Squamous Cell, Head and Neck Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
20172018201920202021202220232024202520262027202820292030
First PostedDec 2016
Enrollment StartApr 2017
Primary CompletionSep 2024
TodayJul 2026
Study CompletionOct 2029
First PostedDec 15, 2016
Enrollment StartApr 11, 2017
Primary CompletionSep 3, 2024
Study CompletionOct 31, 2029
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 9.5 years ago
Interventions
Cisplatindrug
Cisplatin
XRTradiation
Radiation Therapy